WS16.03 Registry-based study of people with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA): Up to 2 years of real-world outcome data

J.K. Bower, C.-Y. Chang,G. Sahota, A. Chin,N. Ahluwalia,C. Chu, T.G. Weinstock, J. Ostrenga,N. Regenfuß, L. Naehrlich

Journal of Cystic Fibrosis（2023）

引用 0|浏览1

暂无评分

摘要

Objectives: To understand long-term effects of ELX/TEZ/IVA under real-world use conditions, a 5-year post-authorization safety study is ongoing. We report results from the second interim analysis (IA).

查看译文

关键词

cystic fibrosis,elexacaftor/tezacaftor/ivacaftor,pwcf,registry-based,real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要